Tissue plasminogen activator to prevent central venous access device infections: A systematic review of central venous access catheter thrombosis, infection and thromboprophylaxis

Haemophilia

Volumn 14, Issue 1, 2008, Pages 30-38

  Ragni, M V ^a   Journeycake, J M ^b   Brambilla, D J ^c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NEW ENGLAND RESEARCH INSTITUTES   (United States)

Author keywords

Central venous access catheter; Haemophilia; Infection; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; BLOOD CLOTTING FACTOR; CATHFLO; DALTEPARIN; ENOXAPARIN; FIBRIN; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PLASMIN; UNCLASSIFIED DRUG; UROKINASE; WARFARIN;

ARTHROPATHY; ARTICLE; BACTEREMIA; CATHETER INFECTION; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; CORRELATION ANALYSIS; DEVICE INFECTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; HEMOPHILIA; HUMAN; IMMUNOLOGICAL TOLERANCE; INFECTION RISK; LOW DRUG DOSE; PHLEBOGRAPHY; PILOT STUDY; PRIORITY JOURNAL; REPEATED DRUG DOSE; SYSTEMATIC REVIEW; THROMBOGENESIS; VASCULAR ACCESS;

CATHETERIZATION, CENTRAL VENOUS; CATHETERS, INDWELLING; CHILD; HUMANS; INFECTION; INFECTION CONTROL; MEDLINE; PREMEDICATION; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 37749012924     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01599.x     Document Type: Article

References (66)

1. Ragni MV, Hord JD, Blatt J. Central venous catheter infection in hemophiliacs undergoing prophylaxis or immune tolerance with clotting factor concentrate. Haemophilia 1997; 3: 90-5.
2. The National Hemophilia Foundation Medical and Scientific Advisory Council (MASAC) Recommendations Concerning Prophylaxis. New York, NY, USA: The National Hemophilia Foundation, Medical Bulletin 193, March 1994.
3. Manco-Johnson MJ, Abshire TC, Shapiro AD et.al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
4. Raad I. Intravascular catheter-related infections. Lancet 1998; 351: 893-8.
5. Crary SE, Buchanan GR, Journeycake JM. Fatal central venous catheter-related infection in haemophilia. Haemophilia 2006; 12: 183-6.
6. Blanchette VS, Al-Musa A, Stain AM, Ingram J, Filler RM. Central venous access devices in children with hemophilia: An update. Blood Coagul Fibrinolysis 1997; 8 (Suppl. 1): S11-4.
7. Perkins JL, Johnson VA, Osip JM et.al. The use of implantable venous access devices (IVADs) in children with hemophilia. J Pediatr Hematol Oncol 1997; 19: 339-44.
8. Warrier I, Baird-Cox K, Lusher J. Use of central venous catheters in children with haemophilia: One haemophilia treatment centre experience. Haemophilia 1997; 3: 194-8.
9. Ljung R, van den Berg M, Petrini P et.al. Port-a-cath usage in children with hemophilia: Experience in 53 cases. Acta Paediatr 1998; 10: 1051-4.
10. Miller K, Buchanan GR, Zappa S et.al. Implantable venous access devices in children with hemophilia: A report of low infection rates. J Pediatr 1998; 132: 934-8.
11. Santagostino E, Gringeri A, Muca-Perja M, Mannucci PM. A prospective clinical trial of implantable central venous access in children with hemophilia. Br J Hematol 1998; 102: 1224-8.
12. Bollard CM, Teague LR, Berry EW, Ockelford PA. The use of central venous catheters (portacaths) in children with hemophilia. Haemophilia 2000; 6: 66-70.
13. McMahon C, Smith J, Khair K, Liesner R, Hann IM, Smith OP. Central venous access devices in congenital coagulation disorders: Complications and long-term outcome. Br J Hematol 2000; 110: 461-8.
14. van Dijk K, van den Berg HM, van der Bom JG. Complications of port-a-cath (PAC) in children with severe hemophilia. Haemophilia 2002; 8: 488.
15. Tusell J, Cid AR, Sosa R, Villar A, Lucia JF. Haemophilia prophylactic treatment in Spain. Haemophilia 2002; 8: 488 and 729-30.
16. Domm JA, Hudson MG, Janco RL. Complications of central venous access devices in pediatric hemophilia patients. Haemophilia 2003; 9: 50-6.
17. Tarantino MD, Lail A, Donfield SM et.al. Surveillance of infectious complications assocated with central venous access devices in children with hemophilia. Haemophilia 2003; 9: 588-92.
18. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in hemophilia: A meta-analysis. Haemophilia 2004; 10: 134-46.
19. van Dijk K, van der bom JG, Bax KN, van der Zee DC, van den Berg MH. Use of implantable venous access devices in children with severe hemophilia: benefits and burden. Haematologica 2004; 89: 189-94.
20. Journeycake JM, Brambilla D, Ragni MV and The Transfusion Medicine Hemostasis Clinical Trials Network. Central venous access device infections in hemophilia. Blood 2005; 106: 3216.
21. Brackmann HH. Induced immunotolerance in factor VIII inhibitor patients. Prog Clin Biol Res 1984; 150: 181-5.
22. Leisner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 973-8.
23. Sandgren T, Sonesson B, Ahlgren AR, Lanne T. The diameter of the common femoral artery in healthy human: Influence of sex, age, and body size. J Vasc Surg 1999; 29: 503-10.
24. Groeger JS, Lucas AB, Thaler HT et.al. Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med 1993; 119: 1168-74.
25. Howell PB, Walters PE, Donowitz GR, Farr BM. Risk factors for infection of adult patients with cancer who have tunneled central venous catheters. Cancer 1995; 75: 1367-75.
26. Maki DG. Infections caused by intravascular devices used for infusion therapy: Pathogenesis, prevention, and management. In: Bistro AI, Waldvogel FA eds. Infections Associated Indwelling Medical Devices, 2nd edn. Washington DC: ASM Pr, 1994: 2.
27. Maki DG, Stolz SM, Wheeler SM, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter: A randomized, controlled trial. Ann Intern Med 1997; 127: 257-66.
28. Reed CR, Sessler CN, Glauser FL, Phelan BA. Central venous catheter infections: Concepts and controversies. Intensive Care Med 1995; 21: 177-83.
29. Asher DP, Shoupe BA, Mabee D, Fischer BW. Persistent catheter-related bacteremia: Clearance with antibiotics and urokinase. J Pediatr Surg 1993; 28: 627-9.
30. King DR, Komer M, Hoffman J et.al. Broviac catheter sepsis: The natural history of an iatrogenic infection. J Pediatr Surg 1985; 20: 728-33.
31. La Quaglia M, Lucas A, Thaler HT, Friedlander-Klar H, Exelby PR, Goreger JS. A prospective analysis of vascular access device-related infections in children. J Pediatr Surg 1994; 27: 840-2.
32. Pearson ML, Abrutyn E. Reducing the risk for catheter-related infection: a new strategy. Ann Intern Med 1997; 127: 304-6.
33. Raad II, Luna M, Sayed-Ahmed M, Costerton JW, Lam C, Bodey GP. The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 1994; 271: 1014-6.
34. Timsit JF, Farkas JC, Boyer JM et.al. Central vein catheter-related thrombosis in intensive care patients: Incidence, risk factors, and relationship with catheter-related sepsis. Chest 1998; 114: 207-13.
35. Stillman RM, Soliman F, Garcia L, Sawyer PN. Etiology of catheter-related sepsis: Correlation with thrombogenicity. Arch Surg 1977; 112: 1497-9.
36. Blanchette VS, Al-Trabolsi H, Stain AM. High risk of central venous line-associated thrombosis in boys with hemophilia. Blood 1999; 94: 818a.
37. Vidler V, Richards M, Vora A. Central venous catheter-associated thrombosis in severe hemophilia. Br J Haematol 1999; 101: 461-4.
38. Journeycake JM, Quinn CT, Miller KL, Zajac JL, Buchanan GR. Catheter-related deep venous thrombosis in children with hemophilia. Blood 2001; 98: 1727-31.
39. Ettingshausen CE, Kurnik K, Schobess R et.al. Catheter-related thrombosis in children with hemophilia A: Evidence of a multifactorial disease. Blood 2002; 99: 1499-500.
40. Nowak-Gottl U, Escuriola C, Kurnik K et.al. Haemophilia and thrombophilia. What do we learn about combined inheritance of both genetic variations? Haemostaseologie 2003; 23: 36-40.
41. Price V, Carcao MD, Connolly BL et.al. A prospective, longitudinal study of central venous catheter- related deep vein thrombosis in boys with hemophilia. J Thromb Haemost 2004; 2: 737-42.
42. Skarja GA, Brash JL. Physicochemical properties and platelet interactions of segmented poly-urethanes containing sulfonate groups in the hard segment. J Biomed Mater Res 1997; 34: 439-55.
43. Ratnoff O, Davie EW. Waterfall sequence for intrinsic blood clotting. Science 1964; 145: 1310-2.
44. Bailey MJ. Reduction of catheter-associated sepsis in parenteral nutrition using low-dose intravenous heparin. Br Med J 1979; 1: 1671-3.
45. Bern MM, Lokich JJ, Wallach SR et.al. Very low doses of warfarin can prevent thrombosis in central venous catheters. Ann Intern Med 1990; 112: 423-8.
46. Barzaghi A, Dell'Orto M, Rovelli A, Rizzari C, Colombini A, Uderzo C. Central venous catheter clots: Incidence, clinical significance and catheter care in patients with hematologic malignancies. Pediatr Hematol Oncol 1995; 12: 243-50.
47. Monreal M, Alastrue A, Rull M et.al. Upper extremity deep venous thrombosis in cancer patients with venous access devices with low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75: 251-3.
48. Randolph AG, Cook DJ, Gonzales CA, Andrew M. Benefit of heparin in central venous and pulmonary artery catheters: A meta-analysis of randomized clinical trials. Chest 1998; 113: 165-71.
49. Boraks P, Seale J, Price J et.al. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematologic malignancies. Br J Haematol 1998; 101: 483-6.
50. Ray CE, Shenoy SS, McCarthy PL, Broderick KA, Kaufman JA. Weekly prophylactic urokinase instillation in tunneled central venous access devices. J Vasc Interv Radiol 1999; 10: 1330-4.
51. Heaton DC, Han DY, Inder A. Minidose (1mg) warfarin as prophylaxis for central vein catheter thrombosis. Intern Med 2002; 32: 84-8.
52. Kalmanti M, Germanakis J, Stiakaki E et.al. Prophylaxis with urokinase in pediatric oncology patients with central venous catheters. Pediatr Hematol Oncol 2002; 19: 173-9.
53. Mainwaring CJ, Naylor E, Jerwood S, Hall V, Page A, James CM. Superior venocaval obstruction secondary to central venous catheter-related thromboses in two patients with metastatic colorectal carcinoma receiving weekly 5-flurouracil. Should adjusted-dose warfarin be used as thromboprophylaxis? Blood Coagul Fibrinolysis 2002; 13: 749-53.
54. Aquino VM, Sandler ES, Mustafa MM, Steele JW, Buchanan GR. A prospective double-blind randomized trial of urokinase flushes to prevent bacteremia resulting from luminal colonization of subcutaneous central venous catheters. J Pediatr Hematol Oncol 2002; 24: 710-3.
55. Klerk CP, Smorenburg SM, Buller HR. Thrombosis prophylaxis in patient populations with a central venous catheter: A systemic review. Arch Intern Med 2003; 163: 1913-21.
56. Dillon PW, Jones GR, Bagnall-Reeb HA, Buckley JD, Wiener ES, Haase GM. Prophylactic urokinase in the management of long-term venous access devices in children: A Children's Oncology Group Study. J Clin Oncol 2004; 22: 2718-23.
57. Herishanu Y, Misgav M, Kirgner I, Ben-Tal O, Eldor A, Naparstek E. Enoxaparin can be safely used in patients with severe thrombocytopenia due to intensive chemotherapy regimens. Leuk Lymphoma 2004; 45: 1407-11.
58. Lersch C, Kotowa W, Fung S, Janssen D. Prophylaxis of port system-associated thromboses in advanced oncology patients using heparin flushing. J Cancer Res Clin Oncol 2004; 130: 235-41.
59. Couban S, Goodyear M, Burnell M et.al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005; 23: 4063-9.
60. Verso M, Agnelli G, Bertoglio S et.al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: A double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005; 23: 4057-62.
61. Tanswell P, Tebbe U, Neuhaus KL, Glasle-Schwarz L, Wojcik J, Seifried E. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. J Am Coll Cardiol 1992; 19: 1071-5.
62. Genentech, Inc. Cathflo® Activase® (Alteplase) Full Prescribing Information: Genentech, Inc., 2005. Available at http://www.gene.com/ gene/products/information/cardiovascular/cathflo-activase/index.jsp. (last accessed 28.09.07).
63. Deitcher SR, Fesen MR, Kiproff PM et.al. The safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines (COOL-2) Trial. J Clin Oncol 2002; 20: 317-24.
64. Semba CP, Deitcher SR, Li X, Resnansky L, Tu T, McCluskey E. Treatment of occluded central venous catheters with alteplase: Results in 1,064 patients. J Vasc Interv Radiol 2002; 13: 1199-205.
65. Hoshal VL, Ause RG, Hoskins PA. Fibrin sleeve formation on indwelling subclavian central venous catheters. Arch Surg 1971; 102: 253-8.
66. De Cicco M, Matovic M, Balestreri L et.al. Central venous thrombosis: An early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study. Thromb Res 1997; 86: 101-13.